Cargando…

Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients

BACKGROUND: The measurement of ESR1 and PIK3CA mutations in plasma cell-free DNA (cfDNA) has been studied as a non-invasive method to quickly assess and monitor endocrine therapy (ET) resistant metastatic breast cancer (MBC) patients. METHODS: The subjects of this retrospective study were a total of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takeshita, Takashi, Yamamoto, Yutaka, Yamamoto-Ibusuki, Mutsuko, Tomiguchi, Mai, Sueta, Aiko, Murakami, Keiichi, Omoto, Yoko, Iwase, Hirotaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581019/ https://www.ncbi.nlm.nih.gov/pubmed/28881720 http://dx.doi.org/10.18632/oncotarget.18479

Ejemplares similares

Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer
por: Takeshita, Takashi, et al.
Publicado: (2018)

Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients
por: Takeshita, Takashi, et al.
Publicado: (2017)

Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients
por: Takeshita, Takashi, et al.
Publicado: (2017)

Prognostic role of PIK3CA mutations of cell‐free DNA in early‐stage triple negative breast cancer
por: Takeshita, Takashi, et al.
Publicado: (2015)

Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients
por: Takeshita, Takashi, et al.
Publicado: (2016)

Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence
por: Sueta, Aiko, et al.
Publicado: (2017)

An Integrative Analysis of PIK3CA Mutation, PTEN, and INPP4B Expression in Terms of Trastuzumab Efficacy in HER2-Positive Breast Cancer
por: Sueta, Aiko, et al.
Publicado: (2014)

APOBEC3B gene expression as a novel predictive factor for pathological complete response to neoadjuvant chemotherapy in breast cancer
por: Fujiki, Yoshitaka, et al.
Publicado: (2018)

The localization of HER4 intracellular domain and expression of its alternately-spliced isoforms have prognostic significance in ER+ HER2- breast cancer
por: Fujiwara, Saori, et al.
Publicado: (2014)

Associations Between Elastography Findings and Clinicopathological Factors in Breast Cancer
por: Hayashi, Mitsuhiro, et al.
Publicado: (2015)

Immunohistochemical analysis in ethinylestradiol-treated breast cancers after prior long-term estrogen-deprivation therapy
por: Omoto, Yoko, et al.
Publicado: (2015)

Fibroblast growth factor receptor‐1 protein expression is associated with prognosis in estrogen receptor‐positive/human epidermal growth factor receptor‐2‐negative primary breast cancer
por: Tomiguchi, Mai, et al.
Publicado: (2016)

Clinical features of lenvatinib treatment in elderly patients with advanced thyroid cancer
por: Suyama, Koichi, et al.
Publicado: (2017)

A progressive and refractory case of breast cancer with Cowden syndrome
por: Sueta, Aiko, et al.
Publicado: (2022)

PTIP Associated protein 1, PA1, Is an Independent Prognostic Factor for Lymphnode Negative Breast Cancer
por: Takeshita, Takashi, et al.
Publicado: (2013)

A comprehensive analysis of Aurora A; transcript levels are the most reliable in association with proliferation and prognosis in breast cancer
por: Yamamoto, Satoko, et al.
Publicado: (2013)

The role of exosomal microRNAs; focus on clinical applications in breast cancer
por: Sueta, Aiko, et al.
Publicado: (2019)

Targeted therapies for ER+/HER2- metastatic breast cancer
por: Yamamoto-Ibusuki, Mutsuko, et al.
Publicado: (2015)

The Clinical Significance of CD169-Positive Lymph Node Macrophage in Patients with Breast Cancer
por: Shiota, Takuya, et al.
Publicado: (2016)

Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer
por: Yamamoto, Yutaka, et al.
Publicado: (2013)

Breast cancers with high DSS1 expression that potentially maintains BRCA2 stability have poor prognosis in the relapse-free survival
por: Rezano, Andri, et al.
Publicado: (2013)

BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study
por: Kosaka, Yoshimasa, et al.
Publicado: (2020)

High density of CD204‐positive macrophages predicts worse clinical prognosis in patients with breast cancer
por: Miyasato, Yuko, et al.
Publicado: (2017)

Identification of biomarkers in ductal carcinoma in situ of the breast with microinvasion
por: Okumura, Yasuhiro, et al.
Publicado: (2008)

Clinical significance of estrogen receptor β in breast and prostate cancer from biological aspects
por: Omoto, Yoko, et al.
Publicado: (2015)

Cardiac computed tomography‐derived myocardial tissue characterization after anthracycline treatment
por: Egashira, Koichi, et al.
Publicado: (2022)

Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study
por: Iwase, H, et al.
Publicado: (2013)

Evaluation of PIK3CA mutations in advanced ER+/HER2-breast cancer in Portugal – U-PIK Project
por: Peixoto, Ana, et al.
Publicado: (2023)

Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers
por: Hutchinson, Katherine E., et al.
Publicado: (2023)

Cardiac computed tomography-derived extracellular volume fraction in late anthracycline-induced cardiotoxicity
por: Egashira, Koichi, et al.
Publicado: (2021)

Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations
por: Ogasawara, Aiko, et al.
Publicado: (2020)

Carcinogenesis of PIK3CA
por: German, Sidra, et al.
Publicado: (2013)

Experiments with relativistic exotic nuclei at the ERS - ESR facilities
por: Geissel, H
Publicado: (1996)

ESR/ERS white paper on lung cancer screening
por: Kauczor, Hans-Ulrich, et al.
Publicado: (2015)

ESR/ERS white paper on lung cancer screening
por: Kauczor, Hans-Ulrich, et al.
Publicado: (2015)

Estrogen Receptor-β Gene Cytosine-Adenine (ESR2-CA) Repeat Polymorphism in Postmenopausal Colon Cancer
por: Honma, Naoko, et al.
Publicado: (2023)

GANP protein encoded on human chromosome 21/mouse chromosome 10 is associated with resistance to mammary tumor development
por: Kuwahara, Kazuhiko, et al.
Publicado: (2016)

PIK3CA in Colorectal Cancer
por: Cathomas, Gieri
Publicado: (2014)

Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval
por: Yamamoto, Yutaka, et al.
Publicado: (2011)

Optimized Immunohistochemical Detection of Rat ESR2 Proteins Using the Specific Anti-ESR2 Monoclonal Antibody PPZ0506
por: Hattori, Yujiro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cs4pum99kr560cl72jh91vi7io